Inhibition of functional osteoblasts with the platelet-derived growth factor receptor (PDGFR) inhibitor imatinib mesylate in androgen-independent prostate cancer (PCa).

被引：0
|
作者：
Mathew, P [1 ]
Yang, J [1 ]
Kim, SJ [1 ]
Fidler, I [1 ]
Bucana, C [1 ]
Troncoso, P [1 ]
Wang, X [1 ]
Thall, P [1 ]
Logothetis, C [1 ]
Navone, N [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4625
引用
收藏
页码：413S / 413S
页数：1
相关论文
共 50 条
  • [1] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
    Hofer, MD
    Rubin, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1332 - 1333
  • [2] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
    Mathew, P
    Thall, PF
    Jones, D
    Perez, C
    Bucana, C
    Troncoso, P
    Kim, SJ
    Fidler, IJ
    Logothetis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3323 - 3329
  • [3] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer - In reply
    Mathew, P
    Fidler, IJ
    Bucana, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1333 - 1334
  • [4] Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
    Mathew, P
    Fidler, IJ
    Logothetis, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 24 - 29
  • [5] Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer
    Altundag, K
    Altundag, O
    Morandi, P
    Gunduz, M
    UROLOGY, 2005, 65 (01) : 211 - 212
  • [6] Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α
    Nayeem, Md Junayed
    Yamamura, Aya
    Hayashi, Hisaki
    Muramatsu, Hiroyuki
    Nakamura, Kogenta
    Sassa, Naoto
    Sato, Motohiko
    LIFE SCIENCES, 2022, 288
  • [7] Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate
    George, DJ
    UROLOGY, 2002, 60 (3A) : 115 - 121
  • [8] Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer - Reply
    Tiffany, NM
    Wersinger, EM
    Beer, TM
    Garzotto, M
    UROLOGY, 2005, 65 (01) : 212 - 212
  • [9] Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate - Discussion
    Sartor, O
    George, DJ
    Balk, SP
    Johnson, CS
    Carroll, PR
    Oh, WK
    Kantoff, PW
    UROLOGY, 2002, 60 (3A) : 122 - 122
  • [10] Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
    Holdhoff, M
    Kreuzer, KA
    Appelt, C
    Scholz, R
    Na, IK
    Hildebrandt, B
    Riess, H
    Jordan, A
    Schmidt, CA
    Van Etten, RA
    Dörken, B
    le Coutre, P
    BLOOD CELLS MOLECULES AND DISEASES, 2005, 34 (02) : 181 - 185
12345